Trial Profile

(Neo)Adjuvant IDE196 (Darovasertib) in Patients With Localized Ocular Melanoma

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 25 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Darovasertib (Primary) ; Metformin; Norethisterone
Indications Uveal melanoma
Focus Adverse reactions; Therapeutic Use
Acronyms NADOM; OptimUM-09
Sponsors IDEAYA Biosciences

Most Recent Events

16 Mar 2026 Status changed from recruiting to active, no longer recruiting.
20 Oct 2025 According to an IDEAYA Biosciences media release, The data from this study were presented in a Proffered Paper oral presentation by Dr. Marcus Butler, M.D., Associate Professor, Princess Margaret Cancer Center at the University of Toronto, at the 2025 European Society of Medical Oncology (ESMO) in Berlin, Germany
20 Oct 2025 Results presented in the IDEAYA Biosciences Media Release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com